Psychedelics to Therapeutics™

January 2022

WWW.CYBIN.COM
The information contained in this presentation must be read and understood by the reader. Cybin Inc. and its affiliates ("Cybin" or the "Company") are a biotechnology company that is focused on developing and commercializing psychedelic-based treatments for brain health and disease, including indications for the treatment of psychiatric diseases and conditions. The material presented in this presentation contains forward-looking information ("FLI"), which is information that does not reflect actual results, performance or achievements of the Company but rather reflects the management’s current expectations, estimates or projections about future events or performance. FLI is usually identified by words or phrases such as "anticipates", "believe", "will be", "estimates", "expects", "intends", "plans", "projects", "predicts", "should", "will", "would", "believe", "requires", "assumes" or similar expressions. The actual results or performance of the Company may differ materially from its expectations, estimates or projections. In particular, our forward-looking statements are subject to various risks and uncertainties, which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the inherent risks and uncertainties of the biotechnology industry, the impact of the ongoing COVID-19 pandemic on the Company’s business and the biotechnology industry generally, regulatory, economic, market and other risks, uncertainties and factors described under the heading "Cautionary Statement Regarding Forward-Looking Information" in this presentation. Additional information identifying forward-looking statements is contained in this presentation. FLI involves substantial risks and uncertainties and should not be interpreted as a guarantee or representation of actual earnings or performance. It is possible that the assumptions of management, the statements contained herein or the underlying economic, market and other factors may not be accurate, complete or relevant and are subject to change over time. Accordingly, the Company disclaims any responsibility for any forward-looking statements contained herein or any responsibility to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

The inclusion of FLI should not be understood or interpreted as a guarantee or representation of actual earnings or performance. The Company has made every effort to ensure that the information in this presentation is accurate and complete, and the Company believes that the information contained herein is current and correct. However, no representation or warranty is made as to the accuracy or completeness of any information herein or that any information contained herein will not infringe the intellectual property of third parties, or that the information is not materially misleading or otherwise not accurate. In addition, any forward-looking statements contained herein are not intended to be a substitute for the Company’s financial statements which are prepared in accordance with generally accepted accounting principles.

The Company has not independently verified any of the data furnished herein, and the reader is encouraged to conduct such verification for himself or herself. The Company is not responsible for any forward-looking statements contained herein or any responsibility to update any forward-looking statements whether as a result of new information, future events or otherwise. The Company assumes no responsibility for any forward-looking statements contained herein or any responsibility to update or change any forward-looking statements whether as a result of new information, future events or otherwise. No representations or warranties are given that the information contained herein is complete or current or that the information furnished in this presentation is accurate or complete in all material respects. No representations or warranties can be made as to the origin, validity, accuracy, completeness, copyright or reliability of the information. Cybin disclaims and excludes all liability (to the extent permitted by law) for losses, claims, damages, demands and expenses of whatever nature arising in any way out of or in connection with the information in this presentation. Its accuracy, completeness or by reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual’s circumstances are different. Readers should consult with their own professional advisors regarding their particular investment circumstances. In making an investment decision, investors should not rely solely on the information contained in this presentation. The delivery of this presentation on or after the date set forth on the first page of the presentation or the date at which such information is expressed to be, or applicable. No securities commission, exchange or similar regulatory authority in Canada or the United States has reviewed or in any way passed upon the merits of this presentation, and any representation to the contrary is an falsehood.

The Company reserves the right to alter any forward-looking statements in this presentation. The Company may change its forward-looking statements, and these changes may or may not be material. Such changes may result from subsequent developments, new information or for other reasons. The Company does not intend to update any forward-looking statements, regardless of whether subsequent developments, new information or for other reasons. The reader should not assume that the Company is obligated to update any forward-looking statements contained herein, regardless of whether subsequent developments, new information or for other reasons. The Company does not undertake any obligation to update or revise any forward-looking statements, regardless of whether subsequent developments, new information or for other reasons. The reader should not assume that the Company is obligated to update or revise any forward-looking statements, regardless of whether subsequent developments, new information or for other reasons.
At Cybin, we are on a mission to engineer transformative psychedelic therapeutics to improve mental health for patients.

Founded in 2019, we are a leading biopharmaceutical company focused on a complete view of our ecosystem by actively engineering:

- proprietary drug discovery platforms
- innovative drug delivery systems
- novel formulation approaches
- treatment regimens for mental health disorders
Corporate and Financial Highlights

- Over C$120M raised to date and well-funded to progress clinical trials, M&A and IP strategies
- **Strategic shareholders** including long-term U.S. institutional funds
- Cash and equivalents of C$75.2m as of September 30, 2021
- Covered by 8 research firms and inclusion in 3 psychedelic ETFs

- Experienced team that has previously brought **multiple drugs** to market
- Grown from 5 to 55 employees across 4 countries (Canada, U.S.A., UK, Ireland)
- Commenced trading in Canada on the **NEO Exchange Inc.** in Nov 2020
- Commenced trading in the U.S. on the **NYSE American** in August 2021 becoming the **first psychedelic company** to be admitted into the NYSE American

**Strong Intellectual Property:**
- Proprietary psychedelic compounds (new chemical entities)
- Integration with delivery platforms
- Methods of use in psychiatric indications
- Drug discovery pipeline of modified and novel tryptamines, phenethylamines and other compounds of interest
2021 Key Milestones

- Developed **50 novel compounds** with **>10 patent filings** across 3 patent families
- Awarded **notice of allowance** from USPTO for **CYB004** for treating anxiety disorders
- Completed **>90 preclinical studies** toward IND filings
- Established **50 professional partnerships** with world-class scientists and CROs
- Received **FDA approval** for first-of-its-kind **neuroimaging study** with psychedelics
- Created **EMBARK™** psychedelic facilitator training program
- Integrated **EMBARK™** in **Phase 2 IIT study** evaluating psilocybin for COVID-affected healthcare providers
- Granted **Schedule I manufacturing license** from DEA to expand internal R&D capabilities
- Grew from 5 to **55 employees** across 4 countries (Canada, U.S., UK and Ireland)
- Became first psychedelic company to qualify for listing on an **NYSE exchange**

**NOTES:**
- Phase 2 investigator-initiated study being conducted by Dr. Anthony Back, professor of medicine (oncology) at the UW School of Medicine and co-funded by Cybin.
- Cybin-sponsored Phase 1 feasibility study evaluating Kernel’s Flow Technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
Strong Leadership Team

Our team has deep rooted psychedelic, pharmaceutical, regulatory and academic research experience

- Successfully helped develop widely used drugs such as: Allegra, Sabril, Anzemet, Vaniqa, Zyprexa, Cymbalta, Neupro & Vimpat
- 300 combined peer reviewed publications by scientific leadership include work in addiction and psychedelics
- Team collectively involved in 37 exits across the biotech sector and various other verticals.
- Overseen 60+ IND programs with FDA
- Worked on the development for the first FDA approved psychedelic compound which is covered by healthcare insurance.
## Research and Development Pipeline

### PROGRAM

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>DISCOVERY</th>
<th>PRECLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>REGISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 Distress</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMBARK—psilocybin for mental distress in frontline healthcare workers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychedelic Effects On Brain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kernel Flow—Neuroimaging Technology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major Depressive Disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYB003—Deuterated Psilocybin Analog</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol Use Disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYB003—Deuterated Psilocybin Analog</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYB004—Deuterated Dimethyltryptamine (DMT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuroinflammation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYB005—Phenethylamine Derivative</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### NOTES:
1. Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Cybin is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocybin and other analogues.
2. Phase 2 investigator initiated study being conducted by Dr. Anthony Back, professor of medicine (oncology) at the UW School of Medicine and co-funded by Cybin.
3. Cybin-sponsored Phase 1 feasibility study evaluating Kernel’s Flow Technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
Unmet Need for Mental Health Disorders

World Health Organization States That Mental Health Disorders Affect More Than 900M People Globally

<table>
<thead>
<tr>
<th>Depression</th>
<th>Alcohol Use Disorder</th>
<th>Anxiety Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>800,000</td>
<td>95,000</td>
<td>5.1% to 11.9%</td>
</tr>
<tr>
<td>Deaths due to suicide globally every year (1)</td>
<td>Estimated alcohol related deaths in the U.S. (3)</td>
<td>General anxiety disorder lifetime prevalence in the United States (4)</td>
</tr>
<tr>
<td>Up to 85%</td>
<td>3M</td>
<td>3% to 7%</td>
</tr>
<tr>
<td>Between 76% and 85% of people in low- and middle-income countries receive no treatment for their disorder (1)</td>
<td>Global deaths attributed to alcohol consumption (3)</td>
<td>Social anxiety disorder lifetime prevalence in the Unites States (4)</td>
</tr>
</tbody>
</table>

The global direct and indirect economic costs from mental disorders is US$2.5 Trillion

---

(1) http://ghdx.healthdata.org/gbd-results-tool
(2) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007565/
Positive Psilocybin Data Supports CYB003 Development

Key finding: In this randomized clinical trial psilocybin-assisted therapy was efficacious in producing rapid and sustained antidepressant effects with large effect sizes* (d=2.5 at week 5 and 2.6 at week 6) in participants with major depressive disorder.

The primary outcome, depression severity was assessed with the GRID–Hamilton Depression Rating Scale (GRID–HAMD) scores at baseline (score of ≥17 required for enrollment). Results support growing evidence suggesting that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects.

Psilocybin was administered in one or two assisted therapy sessions to participants with MDD. There were no significant treatment-related adverse events.

*Effect sizes in well-controlled studies in MDD are traditionally very small, ranging from 0.17 to 0.57
CYB003: Deuterated Psilocybin Analog

**Indication:** Potential to effectively treat major depressive disorder (MDD) and alcohol use disorder (AUD) with potential for reduced side effects associated with other psychedelic therapies currently in development

**MoA:** 5-HT2A-R agonist

**Current status:** IND/CTA filings planned in Q2’22; Phase 1/2a trial initiation in mid-2022

**Completion of IND-enabling development:**
- Preclinical package demonstrating psychedelic activity to support clinical development (efficacy and safety) according to FDA guidelines
- Optimized pharmacokinetic (PK) profile
- Used to predict efficacious and safe human doses

---

**CYB003 Features**

- Less variability in plasma levels
- Faster onset of action
- Shorter duration of effect
- Potentially better tolerability
CYBoo3 could potentially reduce clinic time for patients by 50%.

Cybo03 onset of action is 2X as fast as oral psilocybin.

Cybo03 duration effects are cut in half compared to oral psilocybin.

Data is based on plasma concentration profiles following administration of psilocybin or CYBoo3 to animals.
CYB003 has potential for less adverse effects

Less variability with CYB003 could translate to safer dosing and more predictable patient outcomes

Data is based on plasma concentration profiles following administration of psilocybin or CYB003 to animals
CYB003 could have potentially reduced side effects

Data is based on plasma concentration profiles following administration of psilocybin or CYB003 to animals.

Improved brain to plasma ratio could result in therapeutic effects at lower doses and potential for less side effects.
CYB003 provides therapeutic advantages over oral psilocybin

<table>
<thead>
<tr>
<th>Properties</th>
<th>Psilocybin</th>
<th>CYB003</th>
<th>Potential benefits for patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychedelic effect</td>
<td>✓</td>
<td>✓</td>
<td>Therapeutic potential</td>
</tr>
<tr>
<td>Low variability in plasma levels</td>
<td>X</td>
<td>✓</td>
<td>Safer dosing and more predictable patient outcomes</td>
</tr>
<tr>
<td>Fast onset of action</td>
<td>X</td>
<td>✓</td>
<td>Less down time in clinic and faster onset of effects</td>
</tr>
<tr>
<td>Short total duration of action</td>
<td>X</td>
<td>✓</td>
<td>Shorter clinic days and costs</td>
</tr>
<tr>
<td>Rapid brain distribution</td>
<td>X</td>
<td>✓</td>
<td>Therapeutic effects at lower doses, potentially better tolerability</td>
</tr>
</tbody>
</table>

Source: Company data based on preclinical studies
CYBoo3 Clinical Path to Proof-of-Concept

Key Features:
- Randomized, double-blind, placebo-controlled Phase 1/2a trial design
- Participants receive 2 doses
- Response/remission assessed at Week 3 (after single dose) and at Week 6 (after double dose)

The design allows us to:
- Efficiently move from single HV cohort to MDD patients
- Evaluate range of doses to identify most efficacious dose
- Evaluate more than one administration to identify greatest efficacy

Data Review

- n=6 HV cohort 0.5 mg oral
- n=6 HV cohort 1 mg oral
- n=12 MDD cohort 1 Oral dose 1 tbd
- n=12 MDD cohort 2 Oral dose 2 tbd
- n=12 MDD cohort 3 Oral dose 3 tbd
The Potential of CYB003 for Patients

- **CYB003** shows:
  - 50% less variability in plasma levels (safer dosing and more predictable patient outcomes)
  - 2x faster onset of action (less down time in clinic and faster onset of effects)
  - 50% shorter duration of effect (shorter clinic days and costs)
  - Better brain penetration (therapeutic effects at lower doses, potentially better tolerability)

- Presents opportunity to potentially combine MDD and AUD treatments into single program protected by a family of patent filings resulting in overall cost savings and efficiencies

- Potential to reduce time and resource burden on patients, providers and payers, improving scalability and accessibility of treatment

Source: Company data based on preclinical studies
CYBoo4: Deuterated Dimethyltryptamine (DMT)

**Indication:** Potential to effectively treat anxiety disorders with improved control v. DMT via inhalation

**MoA:** 5-HT2A-R agonist

**Scientific rationale:**
- DMT has agonistic actions on a range of 5-HT receptors
- Efficacy demonstrated in a range of observational and real-world studies in depression, anxiety and substance use disorders

**IP:** Awarded notice of allowance from USPTO that covers new chemical entity claims for CYB004 until 2041

**Current status:** Submit regulatory filing for pilot study in Q2 2022

**CYB004 Features**
- Reduced dose for better safety
- Potential to increase duration of effect
- Potential to alleviate negative experiences v. DMT
**CYB005: Discovery-Phase Phenethylamine Derivative**

**Indication:** Potential to effectively treat neuroinflammation in neurological and psychiatric conditions

**MoA:** 5-HT2A-R agonist lead candidate

**Scientific rationale:**
- Highly potent 5-HT2A agonist
- Excellent brain penetration and limited peripheral exposure
- Induces strong head twitch response *in vivo*
- Extended duration to allow for infrequent dosing

**Development strategy:** Potential partnership opportunity

---

**CYB005 Features**

- Psychoactive compound that activates CNS
- Long duration of action
- Favorable *in vitro* toxicity data
- Good oral bioavailability
Projected Timeline for Developing Psychedelics to Therapeutics

Q1 2022

- Complete CYB003 preclinical studies
- CYB003 Scientific Advice meeting with UK MHRA
- Initiate EMBARK Phase 2 IIT study
- Initiate Kernel Flow feasibility study

Q2 2022

- Submit CYB003 IND and CTA filings with U.S. FDA and UK MHRA
- Submit CYB004 regulatory filing for pilot study
- Nominate CYB005 as partnering candidate

Q3 2022

- Initiate CYB003 Phase 1/2a trial
- Initiate CYB004 pilot study

Q4 2022

- Potential CYB003 interim data readout

Combining a highly capable and effective internal scientific team with external partnerships to rapidly advance our psychedelic-based compounds through development and to patients.
Investment Summary

✓ **Experienced management** team across pharmaceuticals, psychedelics, regulatory, and capital markets with proven track record bringing multiple drugs to market

✓ **Numerous partnerships** with world-class scientists and CROs validate R&D approach

✓ **Robust preclinical pipeline of 50+ novel psychedelic molecules** based upon DMT, MDMA, psilocybin, and other psychedelics with 93 preclinical studies completed to date focusing on faster onset, shorter duration, and scalable treatments

✓ **Multiple active drug programs** targeting major depressive disorder, alcohol use disorder, anxiety disorders, neuroinflammation and treatment-resistant psychiatric disorders

✓ **Human studies for lead asset CYB003** with IND and CTA submissions expected in Q2’22; Phase 1/2a trial initiating in Q3’22

✓ **Psilocybin proof-of-concept readout** from industry peer data de-risks efficacy uncertainty

✓ **Pilot study evaluating CYB004** (deuterated DMT) expected to begin in Q3’22

✓ **Strong and growing IP portfolio** across 3 patent families funded with over C$120m raised to date to progress clinical trials, M&A, and IP strategies

Notes:
- Forward-looking statements are subject to various risks and assumptions. See “Cautionary Notes and Forward-Looking Statements” on page 2 of this presentation.
- Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Cybin is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocybin and other analogues.
- Certain statements regarding psilocybin have not been evaluated by the Food and Drug Administration, Health Canada, or other similar regulatory authorities, nor has the efficacy of psilocybin been confirmed by approved research. There is no assurance that any of the Company’s compounds will be used to diagnose, treat, cure or prevent any disease or condition and robust scientific research and clinical trials are needed.
THANK YOU